DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde

References

Saura C, Oliveira M, Feng YH.
Neratinib + capecitabine vs. lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. JCO ASCO Ann Meeting 2019; #1002.

Download Bibliographical Data

Search in: